CDK4 and venous thromboembolism: The percentages of events of special interest observed in study population treated with CDK4/6 inhibitors during the post-index period were as follows: neutropenia (30.2%), diarrhea (22.4%), hepatic events (20.7%), cardiac rhythm abnormalities (19.8%), venous thromboembolism (4.3%), heart failure (0.9%), and interstitial lung disease (1.7%) (Table S7).